ATTANA AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.076 SEK | +1.33% |
|
+16.92% | -23.23% |
| Sales 2022 | 13.11M 1.2M 95.88M | Sales 2023 | 6.82M 623K 49.89M | Capitalization | 26.99M 2.47M 197M |
|---|---|---|---|---|---|
| Net income 2022 | -14M -1.28M -102M | Net income 2023 | -13M -1.19M -95.1M | EV / Sales 2022 | 3.42 x |
| Net Debt 2022 | 3.24M 296K 23.72M | Net Debt 2023 | 3.18M 291K 23.29M | EV / Sales 2023 | 4.43 x |
| P/E ratio 2022 |
-2.84
x | P/E ratio 2023 |
-1.96
x | Employees | 10 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.9% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.33% | ||
| 1 week | +16.92% | ||
| Current month | +28.81% | ||
| 1 month | +31.03% | ||
| 3 months | -15.56% | ||
| 6 months | -64.32% | ||
| Current year | -23.23% |
1 week
0.08
0.08
1 month
0.060.08
Current year
0.060.12
1 year
0.060.32
3 years
0.061.97
5 years
0.062.40
10 years
0.062.40
| Managers | Title | Age | Since |
|---|---|---|---|
Marcus Söderberg
CEO | Chief Executive Officer | - | 17/09/23 |
| Founder | 54 | 31/12/01 | |
Anders Ulrikson
DFI | Director of Finance/CFO | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 31/12/16 | |
Arne Nabseth
CHM | Chairman | 61 | 30/09/15 |
| Founder | 54 | 31/12/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.076 | +1.33% | 464,206 |
| 25/04/24 | 0.075 | -8.54% | 1,955,795 |
| 24/04/24 | 0.082 | -1.20% | 179,286 |
| 23/04/24 | 0.083 | +10.67% | 263,830 |
| 22/04/24 | 0.075 | +15.38% | 265,434 |
End-of-day quote NORDIC GROWTH MARKET, April 25, 2024
More quotes
Attana AB is a Sweden-based biotechnology company specializing in in vitro characterization of molecular interactions mimicking in vivo conditions. The Company develops proprietary label-free biosensors, based on the Quartz Crystal Microbalance (QCM) technology, for biochemical, crude, sera and cell-based assays. Its products and research services are used by pharmaceutical and biotechnology companies to quality control the production line of a biological pharmaceutical or gain insight into advanced dynamic features of target molecules, as well as by academic institutions within the life sciences. Attanaâs biosensors are used to determine specificity, kinetics and affinity, among other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -23.23% | 2.69M | |
| -20.60% | 128M | |
| -7.82% | 67.46M | |
| +14.87% | 61.68M | |
| +6.64% | 60.58M | |
| +0.60% | 51.45M |
- Stock Market
- Equities
- ATANA Stock
